TVM Capital is to sharpen its investment focus and exclusively invest in healthcare private equity investments in the MENA region and life science venture capital investments in Western Europe and North America.
Investments will be made through TVM’s private equity team TVM Capital MENA, based in Dubai, and through its venture capital team, based in Munich and Montreal.
Dr Helmut Schühsler, chairman of TVM Capital says: "We experience a significant opportunity through the rapid ascension of emerging markets and the MENA region is becoming an attractive investment geography for private equity investment into private healthcare. At the same time, the market for biotechnology company financings has proved to be difficult, with the public market seeing a tremendous surge in interest and public financings being the most important contribution to the industry's well-being in 2013. In our 30-year history we have lived through several bull and bear markets in our target industries and have managed to adjust our strategy and to change the way we do business.
“What has never changed though is our unwavering focus on innovation and quality. I am personally proud of the evolution of our firm into a global investment house with a clear focus on innovation for patients. Bringing innovative solutions to the healthcare market also comes with great return opportunities for our investors."
TVM Capital MENA targets the growing investment opportunity in private sector healthcare across the Middle East and North Africa (MENA), Turkey and India. The Dubai-based firm is led by Schühsler and consists of a team of four investment professionals and more than five executives-in-residence.
Very recently, TVM Capital MENA has signed an affiliation with Spaulding Rehabilitation Network, a US-based global leader in rehabilitative care, long term acute care, home care and related research.
TVM Capital MENA has to date invested in four companies, three are in the broad field of long-term care, home care and fertility. These four companies established their initial operations in the UAE and in the case of our fertility clinic, Bourn Hall International, also North and South India. They are now all in the process of expanding their businesses into other and adjacent regions/countries, such as other states in India, as well as countries in the Middle East, such as Qatar, Kuwait, Oman, Saudi Arabia, Egypt and Jordan. The portfolio companies are on average 25 months old, but already employ close to 500 healthcare professionals and have 2013 revenues of about US$40 million.
Dr Hubert Birner, who leads the TVM Capital life science venture activities together with fellow managing partner Dr Luc Marengere based in Montreal, says: "We continue to invest in Germany, Europe, Canada and the US, with our dedicated team of currently nine investment professionals based in Montreal and Munich. Our new fund TVM Life Science Venture VII gives us the opportunity to invest in exciting life science opportunities at a time when capital is scarce and opportunities are abundant in our preferred investment geographies and beyond."
TVM Capital Life Science is developing a growing focus on Asia and recently entered into a number of collaborations in Korea including one with the Korea Drug Development Fund (KDDF).
